Comparative Pharmacology
Head-to-head clinical analysis: EZALLOR SPRINKLE versus LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EZALLOR SPRINKLE versus LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED.
EZALLOR SPRINKLE vs LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Lansoprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Clarithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
Each dose: Lansoprazole 30 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg administered orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Lansoprazole: ~1.5 h (prolonged in hepatic impairment); Amoxicillin: ~1-1.5 h (prolonged in renal impairment); Clarithromycin: ~3-4 h (6-9 h for 14-hydroxy metabolite).
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Lansoprazole: primarily hepatic metabolism, ~33% renal (metabolites), ~67% fecal; Amoxicillin: ~60-80% renal unchanged; Clarithromycin: ~20-30% renal unchanged, ~50% hepatic metabolism, ~30% fecal.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor